Comparative bioavailability study of two brands of prazosin-containing tablets in healthy volunteers
Articles
- 85 Downloads
Abstract
The bioavailability of two prazosin formulations was studied in 12 healthy volunteers. 1 Subject left the study. Based on the statistical tests of the pharmacokinetic parameters of prazosin in 11 volunteers, such ast1/2,Cmax,tmax and AUC, it could be concluded that both preparations had comparable bioavailabilities.
Keywords
Biological availability Clinical trials Pharmacokinetics PrazosinPreview
Unable to display preview. Download preview PDF.
References
- 1.Benet LZ, Massoud N, Gambertoglio JG. Pharmacokinetic basis for drug treatment. New York: Raven Press, 1984.Google Scholar
- 2.Gilman AG, Goodman LS, Gilman A, Red. Goodman and Gilman's The pharmacological basis of therapeutics. 6th ed. New York: MacMillan Publishing Company, 1980:806–7.Google Scholar
- 3.Hoffman BB. Adrenergic receptor blocking drugs. In: Katzung BG, ed. Basic and clinical pharmacology. Los Altos: Lange Medical Publications, 1984:97–107.Google Scholar
- 4.Rubin PC, Scott PJW, Reid JL. Prazosin disposition in young and elderly subjects. Br J Clin Pharmacol 1981;12:401–4.Google Scholar
- 5.Hobbs DC, Twomey TM, Palmer RV. Pharmacokinetics of prazosin in man. J Clin Pharmacol 1978;18:402–6.Google Scholar
- 6.Jaillon P. Clinical pharmacokinetics of prazosin. Clin Pharmacokinet 1980;5:365–76.Google Scholar
- 7.Verbesselt R, Mullie A, Tjandramaga TB. The effect of food intake on the plasma kinetics and tolerance of prazosin. Acta Ther 1976;2:27–39.Google Scholar
- 8.Lin ET, Baughman RA, Benet LZ. High performance liquid chromatographic determination of prazosin in human plasma, whole blood and urine. J Chromatogr 1980;183:367–71.Google Scholar
- 9.Fluehler H, Grieve AP, Mandallaz D, Mau J, Moser HA. Bayesian approach to bioequivalence assesment: an example. J Pharm Sci 1983;72:1178–81.Google Scholar
- 10.Hauck WW, Anderson S. A new statistical procedure for testing equivalence in two group comparative bioavailability trials. J Pharmacokinet Biopharm 1984;12:83–91.Google Scholar
- 11.Rodda BE, Davis RL. Determining the probability of an important difference in bioavailability. Clin Pharmacol Ther 1980;28:247–52.Google Scholar
- 12.Westlake WJ. Use of confidence intervals in analysis of comparative bioavailability trials. J Pharm Sci 1972;61:1340–1.Google Scholar
- 13.Westlake WJ. Symmetrical confidence intervals for bioequivalence trials. Biometrics 1976;32:741–4.Google Scholar
- 14.Baughman RA, Arnold S, Benet LT, Lin ET, Chatterjee K, Williams RL. Altered prazosin pharmacokinetics in congestive heart failure. Eur J Clin Pharmacol 1980;17:425–8.Google Scholar
- 15.Althuis TH, Hess H-J. Synthesis and identification of the major metabolites of Prazosin formed in dog and rat. J Med Chem 1977;20:146–9.Google Scholar
- 16.Runkel R, Forchielli E, Boost G, et al. Naproxen metabolism, excretion, and comparative pharmacokinetics. Scand J Rheumatol 1973;2:29–36.Google Scholar
- 17.Taylor JA, Twomey TM, Schach von Wittenau M. The metabolic fate of Prazosin. Xenobiotica 1977;7:357–64.Google Scholar
- 18.Antilla M, Haataja M, Kasanen A. Pharmacokinetics of naproxen in subjects with normal and impaired renal function. Eur J Clin Pharmacol 1980;18:263–8.Google Scholar
Copyright information
© Royal Dutch Association for Advancement of Pharmacy 1990